Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
103.37
-2.46 (-2.32%)
At close: Dec 26, 2025, 4:00 PM EST
103.94
+0.57 (0.55%)
After-hours: Dec 26, 2025, 4:10 PM EST
Palvella Therapeutics Stock Forecast
Stock Price Forecast
The 16 analysts that cover Palvella Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $141.5, which forecasts a 36.89% increase in the stock price over the next year. The lowest target is $38 and the highest is $204.
Price Target: $141.5 (+36.89%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Palvella Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 8 | 9 | 12 |
| Buy | 1 | 3 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 11 | 12 | 12 | 13 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $105 → $190 | Strong Buy | Maintains | $105 → $190 | +83.81% | Dec 16, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $148 → $204 | Strong Buy | Maintains | $148 → $204 | +97.35% | Dec 16, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $97 → $133 | Strong Buy | Maintains | $97 → $133 | +28.66% | Dec 16, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $110 → $174 | Strong Buy | Maintains | $110 → $174 | +68.33% | Dec 16, 2025 |
| BTIG | BTIG | Strong Buy Maintains $167 → $192 | Strong Buy | Maintains | $167 → $192 | +85.74% | Dec 15, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
34.00K
EPS This Year
-3.57
from -7.83
EPS Next Year
-3.95
from -3.57
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 420,000 | ||||
| Avg | n/a | 33,997 | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.00 | -3.09 | ||||
| Avg | -3.57 | -3.95 | ||||
| Low | -3.57 | -4.82 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.